# Clinical Trials Data KRAS - Document 33

# Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

## Clinical Trial: https://clinicaltrials.gov/study/NCT01124669

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of refractory non-small cell lung cancer\n\* Received sorafenib tosylate on protocol ECOG-E2501\n\* Available blood specimens\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Samples submitted for research from patients enrolled on E2501",

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
This eligibility criteria does \*not\* mention anything about KRAS mutation status. Therefore, having a KRAS mutation would neither include nor exclude a patient from this trial based on the information provided. The key criteria are:  
  
\* \*\*Diagnosis of refractory non-small cell lung cancer:\*\* The patient must have this diagnosis.  
\* \*\*Prior treatment with sorafenib tosylate on protocol ECOG-E2501:\*\* This is a crucial inclusion criterion. The trial is specifically for patients who have already participated in the ECOG-E2501 study and received sorafenib.  
\* \*\*Available blood specimens:\*\* Samples are required for the research.  
  
Whether a patient has a KRAS mutation is irrelevant based on this description.